S1900E: A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)

About this Study

Lung MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer (NSCLC) that is stage IV or has come back (recurrent) and has a specific mutation in the KRAA gene, known as KRAS  G12C.

Sponsor Protocol ID:S1900E
IRB Number:2021-0600
Phase 2
July 19, 2022
Eligibility Criteria
18 years old
Both Male and Female

Inclusion Criteria
  • Must have confirmed stage IV or recurrent non-squamous non-small cell lung cancer
  • Must have measurable disease documented by CT or MRI
  • Patients with spinal cord compression or brain metastases must have received local treatment to these metastases and remained clinically controlled and asymptomatic for at least 7 days following stereotactic¬† radiation and/or 14 day following whole brain radiation
  • Must have received at least one line of systemic treatment for stage IV or recurrent NSCLS

Exclusion Criteria
  • Patients with spinal cord compression or brain metastases must not have residual neurological dysfunction
  • Leptomeningeal disease unless (1) asymptomatic and (2) only detected on radiographic imaging
  • Received any prior systemic therapy within 21 days prior to sub-study registration
  • Received any radiation therapy within 14 days prior to sub-study registration
  • Received prior AMG 510 or other KRAS G12C specific inhibitor
  • Planning to receive any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment while receiving treatment on this study
  • Had a major surgery within 14 days prior to sub study registration
  • Any grade III/IV cardiac disease, unstable angina pectoris, and myocardial infarction within 6 months, or serious uncontrolled cardiac arrhythmia
  • Prior or concurrent malignancy¬†
  • Gastrointestinal disorders that my impact drug absorption
  • Pregnant or nursing

Categories Click category to view its trials.
Participating Locations
Cancer Center and Research Institute - UMMC
University Hospital - UMMC
Contact Information
Contact Name: Eulisa Goins-Freeman
Phone Number: 601-815-3936
Email: efreeman2@umc.edu
Principal Investigator:Morgan, Dennis P, M.D.
How to participate in our Clinical Trials